12:00 AM
Sep 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AKB-6548: Phase I started

Akebia began a double-blind, placebo-controlled, single ascending-dose, U.S. Phase I trial to evaluate oral AKB-6548 in up to 48 healthy volunteers....

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >